               SEQUENCE LISTING

<110> Bayer Pharma Aktiengesellschaft

<120> Novel Aryl-cyanoguanidine Compounds

<130> BHC153016FC

<160> 3

<170> BiSSAP 1.3

<210> 1
<211> 470
<212> PRT
<213> synthetic organisms

<220> 
<223> human SMYD2 with N-terminal His tag before cleavage by TEV
      protease

<400> 1
Met Thr Ser His His His His His His Ser Ser Met Gly Ser Arg Thr 
1               5                   10                  15      
Ser Leu Tyr Lys Lys Ala Gly Ser Asp Tyr Asp Ile Pro Thr Thr Glu 
            20                  25                  30          
Asn Leu Tyr Phe Gln Gly Arg Ala Glu Gly Leu Gly Gly Leu Glu Arg 
        35                  40                  45              
Phe Cys Ser Pro Gly Lys Gly Arg Gly Leu Arg Ala Leu Gln Pro Phe 
    50                  55                  60                  
Gln Val Gly Asp Leu Leu Phe Ser Cys Pro Ala Tyr Ala Tyr Val Leu 
65                  70                  75                  80  
Thr Val Asn Glu Arg Gly Asn His Cys Glu Tyr Cys Phe Thr Arg Lys 
                85                  90                  95      
Glu Gly Leu Ser Lys Cys Gly Arg Cys Lys Gln Ala Phe Tyr Cys Asn 
            100                 105                 110         
Val Glu Cys Gln Lys Glu Asp Trp Pro Met His Lys Leu Glu Cys Ser 
        115                 120                 125             
Pro Met Val Val Phe Gly Glu Asn Trp Asn Pro Ser Glu Thr Val Arg 
    130                 135                 140                 
Leu Thr Ala Arg Ile Leu Ala Lys Gln Lys Ile His Pro Glu Arg Thr 
145                 150                 155                 160 
Pro Ser Glu Lys Leu Leu Ala Val Lys Glu Phe Glu Ser His Leu Asp 
                165                 170                 175     
Lys Leu Asp Asn Glu Lys Lys Asp Leu Ile Gln Ser Asp Ile Ala Ala 
            180                 185                 190         
Leu His His Phe Tyr Ser Lys His Leu Gly Phe Pro Asp Asn Asp Ser 
        195                 200                 205             
Leu Val Val Leu Phe Ala Gln Val Asn Cys Asn Gly Phe Thr Ile Glu 
    210                 215                 220                 
Asp Glu Glu Leu Ser His Leu Gly Ser Ala Ile Phe Pro Asp Val Ala 
225                 230                 235                 240 
Leu Met Asn His Ser Cys Cys Pro Asn Val Ile Val Thr Tyr Lys Gly 
                245                 250                 255     
Thr Leu Ala Glu Val Arg Ala Val Gln Glu Ile Lys Pro Gly Glu Glu 
            260                 265                 270         
Val Phe Thr Ser Tyr Ile Asp Leu Leu Tyr Pro Thr Glu Asp Arg Asn 
        275                 280                 285             
Asp Arg Leu Arg Asp Ser Tyr Phe Phe Thr Cys Glu Cys Gln Glu Cys 
    290                 295                 300                 
Thr Thr Lys Asp Lys Asp Lys Ala Lys Val Glu Ile Arg Lys Leu Ser 
305                 310                 315                 320 
Asp Pro Pro Lys Ala Glu Ala Ile Arg Asp Met Val Arg Tyr Ala Arg 
                325                 330                 335     
Asn Val Ile Glu Glu Phe Arg Arg Ala Lys His Tyr Lys Ser Pro Ser 
            340                 345                 350         
Glu Leu Leu Glu Ile Cys Glu Leu Ser Gln Glu Lys Met Ser Ser Val 
        355                 360                 365             
Phe Glu Asp Ser Asn Val Tyr Met Leu His Met Met Tyr Gln Ala Met 
    370                 375                 380                 
Gly Val Cys Leu Tyr Met Gln Asp Trp Glu Gly Ala Leu Gln Tyr Gly 
385                 390                 395                 400 
Gln Lys Ile Ile Lys Pro Tyr Ser Lys His Tyr Pro Leu Tyr Ser Leu 
                405                 410                 415     
Asn Val Ala Ser Met Trp Leu Lys Leu Gly Arg Leu Tyr Met Gly Leu 
            420                 425                 430         
Glu His Lys Ala Ala Gly Glu Lys Ala Leu Lys Lys Ala Ile Ala Ile 
        435                 440                 445             
Met Glu Val Ala His Gly Lys Asp His Pro Tyr Ile Ser Glu Ile Lys 
    450                 455                 460                 
Gln Glu Ile Glu Ser His 
465                 470 

<210> 2
<211> 433
<212> PRT
<213> synthetic organisms

<220> 
<223> human SMYD2 after cleavage by TEV protease

<400> 2
Gly Arg Ala Glu Gly Leu Gly Gly Leu Glu Arg Phe Cys Ser Pro Gly 
1               5                   10                  15      
Lys Gly Arg Gly Leu Arg Ala Leu Gln Pro Phe Gln Val Gly Asp Leu 
            20                  25                  30          
Leu Phe Ser Cys Pro Ala Tyr Ala Tyr Val Leu Thr Val Asn Glu Arg 
        35                  40                  45              
Gly Asn His Cys Glu Tyr Cys Phe Thr Arg Lys Glu Gly Leu Ser Lys 
    50                  55                  60                  
Cys Gly Arg Cys Lys Gln Ala Phe Tyr Cys Asn Val Glu Cys Gln Lys 
65                  70                  75                  80  
Glu Asp Trp Pro Met His Lys Leu Glu Cys Ser Pro Met Val Val Phe 
                85                  90                  95      
Gly Glu Asn Trp Asn Pro Ser Glu Thr Val Arg Leu Thr Ala Arg Ile 
            100                 105                 110         
Leu Ala Lys Gln Lys Ile His Pro Glu Arg Thr Pro Ser Glu Lys Leu 
        115                 120                 125             
Leu Ala Val Lys Glu Phe Glu Ser His Leu Asp Lys Leu Asp Asn Glu 
    130                 135                 140                 
Lys Lys Asp Leu Ile Gln Ser Asp Ile Ala Ala Leu His His Phe Tyr 
145                 150                 155                 160 
Ser Lys His Leu Gly Phe Pro Asp Asn Asp Ser Leu Val Val Leu Phe 
                165                 170                 175     
Ala Gln Val Asn Cys Asn Gly Phe Thr Ile Glu Asp Glu Glu Leu Ser 
            180                 185                 190         
His Leu Gly Ser Ala Ile Phe Pro Asp Val Ala Leu Met Asn His Ser 
        195                 200                 205             
Cys Cys Pro Asn Val Ile Val Thr Tyr Lys Gly Thr Leu Ala Glu Val 
    210                 215                 220                 
Arg Ala Val Gln Glu Ile Lys Pro Gly Glu Glu Val Phe Thr Ser Tyr 
225                 230                 235                 240 
Ile Asp Leu Leu Tyr Pro Thr Glu Asp Arg Asn Asp Arg Leu Arg Asp 
                245                 250                 255     
Ser Tyr Phe Phe Thr Cys Glu Cys Gln Glu Cys Thr Thr Lys Asp Lys 
            260                 265                 270         
Asp Lys Ala Lys Val Glu Ile Arg Lys Leu Ser Asp Pro Pro Lys Ala 
        275                 280                 285             
Glu Ala Ile Arg Asp Met Val Arg Tyr Ala Arg Asn Val Ile Glu Glu 
    290                 295                 300                 
Phe Arg Arg Ala Lys His Tyr Lys Ser Pro Ser Glu Leu Leu Glu Ile 
305                 310                 315                 320 
Cys Glu Leu Ser Gln Glu Lys Met Ser Ser Val Phe Glu Asp Ser Asn 
                325                 330                 335     
Val Tyr Met Leu His Met Met Tyr Gln Ala Met Gly Val Cys Leu Tyr 
            340                 345                 350         
Met Gln Asp Trp Glu Gly Ala Leu Gln Tyr Gly Gln Lys Ile Ile Lys 
        355                 360                 365             
Pro Tyr Ser Lys His Tyr Pro Leu Tyr Ser Leu Asn Val Ala Ser Met 
    370                 375                 380                 
Trp Leu Lys Leu Gly Arg Leu Tyr Met Gly Leu Glu His Lys Ala Ala 
385                 390                 395                 400 
Gly Glu Lys Ala Leu Lys Lys Ala Ile Ala Ile Met Glu Val Ala His 
                405                 410                 415     
Gly Lys Asp His Pro Tyr Ile Ser Glu Ile Lys Gln Glu Ile Glu Ser 
            420                 425                 430         
His 
    

<210> 3
<211> 20
<212> PRT
<213> synthetic organisms

<220> 
<223> biotinylated peptide

<400> 3
Gly Ser Arg Ala His Ser Ser His Leu Lys Ser Lys Lys Gly Gln Ser 
1               5                   10                  15      
Thr Ser Arg His 
            20  

